Physician profile
Daniel Lew
NPI 1427462274
$583.35
in general payments reported to CMS, 2019-2025
16 companies · $476 in 2025
The $476 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $107 · 2025: $476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $583.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $583.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $130.21 | 2024-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $76.30 | 2025 | Zepbound, Mounjaro, Kisunla |
| Pfizer INC. | $60.94 | 2024-2025 | |
| Aimmune Therapeutics, INC. | $50.84 | 2024-2025 | Zenpep |
| Medtronic, INC. | $43.96 | 2025 | Symplicity G3 |
| Amgen INC. | $31.10 | 2025 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $29.36 | 2025 | Rexulti |
| Glaxosmithkline, LLC. | $26.53 | 2025 | Shingrix, Arexvy |
| Corium, LLC | $23.82 | 2024 | Azstarys |
| Cranial Technologies, INC | $19.36 | 2025 | Doc Band |
| Insulet Corporation | $18.74 | 2025 | Omnipod |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.83 | 2025 | Caplyta |
| Vertical Pharmaceuticals, LLC | $16.53 | 2025 | Relexxii |
| Sanofi Pasteur INC. | $14.84 | 2024 | |
| Sanofi-Aventis U.S. LLC | $14.48 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| The Binding Site INC. | $9.51 | 2025 | Freelite |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Lew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.